Drug Profile
SL 501
Alternative Names: SL-501Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Scott & White Healthcare
- Developer Stemline Therapeutics
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Hodgkin's disease; Non-Hodgkin's lymphoma
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA
- 28 Jan 2024 No recent reports of development identified for preclinical development in Chronic-myelomonocytic-leukaemia in USA
- 28 May 2022 No recent reports of development identified for preclinical development in Hodgkin's-disease in USA